scholarly journals Critical role of gap junction communication, calcium and nitric oxide signaling in bystander responses to focal photodynamic injury

Oncotarget ◽  
2015 ◽  
Vol 6 (12) ◽  
pp. 10161-10174 ◽  
Author(s):  
Bianca Calì ◽  
Stefano Ceolin ◽  
Federico Ceriani ◽  
Mario Bortolozzi ◽  
Andrielly H.R. Agnellini ◽  
...  
2010 ◽  
Vol 24 (S1) ◽  
Author(s):  
Adam C. Straub ◽  
Scott R. Johnstone ◽  
Angela K. Best ◽  
Lisa Palmer ◽  
Brant E. Isakson

2010 ◽  
Vol 285 (31) ◽  
pp. 23970-23984 ◽  
Author(s):  
Shigemoto Fujii ◽  
Tomohiro Sawa ◽  
Hideshi Ihara ◽  
Kit I. Tong ◽  
Tomoaki Ida ◽  
...  

1998 ◽  
Vol 5 (1) ◽  
pp. 115A-115A
Author(s):  
K CHWALISZ ◽  
E WINTERHAGER ◽  
T THIENEL ◽  
R GARFIELD
Keyword(s):  

Physiology ◽  
2013 ◽  
Vol 28 (4) ◽  
pp. 216-224 ◽  
Author(s):  
John W. Calvert ◽  
David J. Lefer

Exercise promotes cardioprotection in both humans and animals not only by reducing risk factors associated with cardiovascular disease but by reducing myocardial infarction and improving survival following ischemia. This article will define the role that nitric oxide and β-adrenergic receptors play in mediating the cardioprotective effects of exercise in the setting of ischemia-reperfusion injury.


1995 ◽  
Vol 10 (6) ◽  
pp. 270-282
Author(s):  
Stella Kourembanas

Persistent pulmonary hypertension of the newborn (PPHN) is a common cause of respiratory failure in the full-term neonate. Molecular and cellular studies in vascular biology have revealed that endothelial-derived mediators play a critical role in the pathogenesis and treatment of PPHN. Endothelial-derived vasoconstrictors, like endothelin, may increase smooth muscle cell contractility and growth, leading to the physiologic and structural changes observed in the pulmonary arterioles of infants with this disease. On the other hand, decreased production of the endothelial-derived relaxing factor, nitric oxide, may exacerbate pulmonary vasoreactivity and lead to more severe pulmonary hypertension. Exogenous (inhaled) nitric oxide therapy reduces pulmonary vascular resistance and improves oxygenation. The safety and efficacy of this therapy in reducing the need for extracorporeal membrane oxygenation and decreasing long-term morbidity is being tested in several trials nationally and abroad. Understanding the basic mechanisms that regulate the gene expression and production of these vasoactive mediators will lead to improved preventive and therapeutic strategies for PPHN.


2009 ◽  
Vol 171 (5) ◽  
pp. 513-520 ◽  
Author(s):  
Sylvain Gaillard ◽  
David Pusset ◽  
Sonia M. de Toledo ◽  
Michel Fromm ◽  
Edouard I. Azzam

1999 ◽  
Vol 5 (12) ◽  
pp. 812-819 ◽  
Author(s):  
M. Djavad Mossalayi ◽  
Pierre-André Becherel ◽  
Patrice Debré

Sign in / Sign up

Export Citation Format

Share Document